Adult Immunization

Anaphylaxis

Food Allergies

Seasonal Allergies

Allergy

Atrial Fibrillation

Cardiovascular Disease

Heart Failure

Hypertension

Lipid disorders

Cardiology

Atopic Dermatitis

Psoriasis

Rosacea

Dermatology

Adrenal Disorders

Diabetes

Diabetes Type 2

Thyroid Disorders 

Endocrinology 

C Difficile Infection

Celiac disease

GERD

Inflammatory Bowel Disease

Irritable Bowel Syndrome 

Gastroenterology

Geriatrics

Hepatitis

MASLD/MASH

Hepatology

C difficile

Cold, Cough, and Flu

Coronavirus

HIV AIDS

Hepatitis C

Immunization

Influenza

Pneumonia

Sexually transmitted infections

Infectious Disease

Chronic Kidney Disease

Nephrology

Alzheimer Disease/Dementia

Cerebrovascular Diseases

Dementia

Epilepsy

Headache

Headache and Migraine

Mental Health

Migraine

Nervous System Diseases

Parkinson Disease

Sleep Disorders

Stroke

Neurology

Obesity Medicine

Oncology

Fibromyalgia

Pain Management

Pediatric Immunization

Child/Adolescent

Pediatrics

ADHD

Anxiety

Depression

Eating Disorders

PTSD

Panic Disorder  

Psychosis

Substance-related Disorders

Psychiatry 

Asthma

COPD

Cystic Fibrosis

Interstitial lung disease

Pulmonary hypertension

Respiratory Diseases

Pulmonology

Gout

Lupus

Osteoarthritis

Psoriatic arthritis

Rheumatoid Arthritis

Rheumatology

Breast Cancer

Cervical Cancer

Colorectal Cancer

Lung Cancer

Melanoma

Prostate Cancer

Renal Cancer

Skin cancer

Screening

Menopause

Osteoporosis

Pregnancy and Birth

Women's Health

News

All News

Editorial Podcasts

Practice Management

Video Interviews

Media

Around the Practice

Between the Lines

ConsultantLive

Frontline Insights

Institutional Insights

Primary View

Provider Toolkits

Conferences

Conference Coverage

Conference Listing

Product Theater Recaps

Resources

Interactive Posters

Product Profile

Publications

Subscribe

CE/CME

About Us

Advertise

Contact Us

Editorial Board

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Men’s Health

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Technology

Telehealth

Value-based Care

Spotlight

VMS and Menopause

Early Identification of Alzheimer's Disease

Adult Immunization Center

Dermatology Hot Topics

1rem

Authors

A 67-year-old woman noted the appearance of several non-tender, rock-hard, purple-colored nodules on her legs. Her medical history was significant for distant non-Hodgkin lymphoma.

A 67-year-old woman noted the appearance of several non-tender, rock-hard, purple-colored nodules on her legs. Her medical history was significant for distant non-Hodgkin lymphoma. The violaceous color and configuration of the skin lesions suggests which of the following? 

Clinical Topics

Hard Purple Nodules: Your Dx?

A 76-year-old woman seeks your attention for an asymptomatic “red spot” on her neck. She has a history of multiple non-melanoma skin cancers.

Squamous cell carcinoma in situ (Bowen  disease)

Lichenoid keratosis (an inflammatory variant of seborrheic keratosis)

A 76-year-old woman seeks your attention for an asymptomatic “red spot” on her neck. What does this look like to you?

What's This "Red Spot"?

The landscape of type 2 diabetes management is rapidly evolving with continuous glucose monitoring (CGM) continuing to demonstrate its power for improving glycemic control. At the ACP Internal Medicine Meeting 2025 in New Orleans, Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, CDCES

presented compelling evidence and practical guidance on implementing CGM for patients with type 2 diabetes using insulin in primary care settings.

began the session with a critical assessment of hemoglobin HbA1c (HbA1c) as the traditional metric for diabetes management. While HbBA1c remains valuable, CGM offers a more comprehensive view of glycemic patterns, including presentation of retrospective data that allows assessment of glucose patterns over time. Martens presented results from recent meta-analyses comparing CGM versus blood glucose monitoring (BGM) in type 2 diabetes that showed a statistically significant 0.33% HbA1c difference, favoring CGM. 

Perhaps more importantly, Martens emphasized the growing body of evidence linking time in range (TIR) with diabetes complications. Multiple cross-sectional and longitudinal studies have demonstrated associations between lower TIR and albuminuria, retinopathy, peripheral neuropathy, cardiac autonomic neuropathy, abnormal carotid intima-media thickness, and higher cardiovascular mortality.

CGM Technology: Current Options and Landscape

Martens offered a look at the "landscape" of CGM systems now available,  distinguishing between:

 (rtCGM): Patient-owned systems that continuously measure and display glucose data (eg, Dexcom G6/G7, Freestyle Libre 3+)

 (isCGM): Patient-owned systems that measure continuously but display data only when scanned (eg, Freestyle Libre 2+)

 Clinic-owned systems placed on patients for 7-14 days (eg, Dexcom G6 Pro, Freestyle Libre Pro)

He also reviewed the recent clearance in the US of over-the-counter CGM systems as a significant development. The Dexcom Stelo and Abbott Rio are appropriate for people with prediabetes and diabetes who are not on insulin. The OTC systems do not have alerts for hypoglycemia making them inappropriate for those individuals, Martens stressed. Along with the Abbot Lingo, all 3 of the systems promote their use for general health monitoring. 

Interpreting CGM Data: A Systematic Approach

Martens then turned the presentation over to his colleague at the International Diabetes Center (IDC) Gregg Simonson, PhD, who walked through the IDC's  "Determine Where to Act" framework that provides a structured approach to interpreting CGM data and adjusting treatment based on glycemic patterns. 

Is TIR (70-180 mg/dL) >70%? Is time below range (TBR) <70 mg/dL <4%?

: Review the ambulatory glucose profile (AGP) curve

Identify patterns of hypoglycemia, hyperglycemia, or variability

Ask the patient what THEY see in the AGP report

: Use shared decision making with the patient to adjust medications and lifestyle

Remember that every 5% improvement in TIR is clinically beneficial

 patients about the retrospective data. Review the curves with them. Ask them questions about activities or food choices when glycemia is high or about how they are using insulin when levels dip below <70 mg/dL. The visual information available with CGM is offers valuable teaching opportunities.  

Simonson reviewed in detail a second IDC resource for individuals with type 2 diabetes who require insulin. The Clinician CGM Guided Management (CCGM) framework categorizes patients into 4 categories based on TIR and TBR:

TIR >70%, TBR <3%: Continue current regimen - this is the ideal 

 Address hypoglycemia immediately and consider referral for additional support from a diabetes educator or even to an endocrinology colleague, 

The framework provides specific medication adjustment recommendations for each category, considering the patient's current insulin regimen (basal only, basal-bolus, or premixed).

Before using the CCGM TIR/TBR tables, however, Simonson advised on steps to ensure an individual's current medication regimen is optimal. 

: Assess the patient for comorbid disease, ie, established atherosclerotic cardiovascular disease, congestive heart failure, or chronic kidney disease? These are indications for adding either a GLP-1 mimetic or SGLT-2 inhibitor therapy.

 D/C the S/U. Is the patient on a sulfonylurea as well as insulin therapy? If so, to avoid hypoglycemia, consider stopping the sulfonylurea if basal insulin is the current regimen and stop the medication if the patient is on either basal-bolus or premixed insulin.

Assess changes based on implementing Steps 1 and 2. If no change has occurred, move on to the CCGM tables to further fine-tune insulin use based on  of the 4 categories of glycemic control. If the optimization changes were effective, wait 2 to 4 weeks before moving on to the CCGM framework, Simonson advised.

Case Studies: Putting Theory into Practice

The presentation included detailed case studies that applied the CCGM framework to real-world scenarios:

 - A 55-year-old man with T2D for 13 years, on metformin, semaglutide, and basal insulin. His CGM data showed TIR of 47% with no hypoglycemia (category 3, above). Following the CCGM guidance, his basal insulin was increased by 10% (from 42 to 46 units) along with nutrition counseling. At 3-month follow-up, his TIR had improved dramatically to 93%.

 - A 61-year-old woman with T2D for 12 years, on basal-bolus insulin, metformin, and dulaglutide. Her CGM showed TIR of 39% with minimal hypoglycemia (Category 3). Her regimen was adjusted by increasing total daily insulin by 10% and redistributing to a 50:50 ratio between basal and bolus insulin.

Martens then addressed several practical aspects of implementing CGM:

ACP 2025. Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, LD, CDCES explained the benefits of CGM, how to interpret data, and then adjust treatment accordingly. 

Continuous Glucose Monitoring vs HbA1c: A Deep Dive into CGM Data and How to Use It  

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP

Articles

Latest Updated Articles